PerkinElmer to showcase expanded life science/cell & gene therapy portfolios and automated genomic workflows at SLAS 2022
The end-to-end solutions are designed to help scientists streamline and improve drug discovery R&D productivity
7 Feb 2022
Industry news
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, is at SLAS 2022 along with several of its new partner companies showcasing how its end-to-end life science solutions and automated workflows can accelerate scientists’ R&D productivity and in turn get the right therapeutic candidates to market faster.
The differentiated offerings and novel workflows highlighted include instruments, assays and reagents, consumables, automation technologies, software, and services that span across basic research, biologics, and cell and gene drug discovery and development.
Innovators from across PerkinElmer and its new partner companies Horizon Discovery, BioLegend, Nexcelom Bioscience, and Omni International are in Boston for the industry gathering sharing leading technologies and solutions critical for today’s labs - from automation, liquid handling, high-content screening, cell painting, multimode detection, gene editing tools, and functional genomic screening services and libraries, to cell counting, antibodies for flow cytometry, recombinant proteins and no-wash immunoassay kits.
PerkinElmer presents a walkaway workflow solution for protein-protein interaction (PPI) immunoassay development. This workflow is fully automated once the reagents are placed on the JANUS® G3 Assay Development Workstation integrated with the VICTOR™ Nivo® multimode microplate reader. No automation programming is required, as TIBCO® Spotfire® software is configured as a graphical user interface (GUI) to interactively design plate layouts and add meta data by user input. The solution is enabled through homogeneous time resolved fluorescence (HTRF®) immunoassay technology which requires no wash steps. Signals VitroVivo™ software is used for analyzing the data and as a recommendation engine to provide conditions for the next set of experiments. The workflow components are integrated for a complete data flow with rationale and traceability of each well fully documented.
Also on display is the FlexDrop™ iQ™ Non-contact Dispenser. To further reduce the cost and time associated with the drug discovery process, it provides rapid and precise dispensing as low as eight nanoliters and can be programmed and run from the integrated touch screen. Additionally, the Honeycomb Biotechnologies, Inc. HIVE™ scRNAseq solution for single-cell isolation and analysis is featured at SLAS. It leverages a portable handheld device for the capture, storage, and RNA-Seq library prep of a diverse range of cell types, requires no specialized instrumentation, and expands opportunities for laboratories pursuing basic, translational, preclinical, and clinical research.
PerkinElmer and its partner company experts are also delivering several presentations ranging from advancements in pooled and arrayed CRISPR-Cas9 screening, next-generation HCS data management and analysis, and cell counting to PPI assay development and more.
PerkinElmer has also broadened its collaboration with biotechs and will jointly present two outcomes: An orthogonal approach for antibody characterization by high throughput Surface Plasmon Resonance (HT SPR) with Carterra and combined no-wash immunoassay by PerkinElmer’s AlphaLISA® kit. A new concept for target engagement using CETSA®ble kits will be presented with the Swedish Pelago Biosciences team. Additionally, Dr. Daniel LaBarbera, from The Center for Drug Discovery at the University of Colorado Anschutz Medical Campus will discuss his new lab’s use of PerkinElmer’s high throughput drug discovery technologies for cancer research. For complete details, view the full presentation schedule.
“The life science industry is changing the way it does drug discovery and development and PerkinElmer is changing too,” said Alan Fletcher, senior vice president life science at PerkinElmer. “Together with our strategic company partners, our expanded scientific portfolio and multi-disciplined team create unique synergies and a blended offering to help our customers overcome challenges in speed, productivity, and success rates.”